TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parental Participation in Individually Customized Physiotherapy for Preterm Infants in the Neonatal Intensive Care Unit: Effects and Experiences. The Pragmatic Randomized Controlled Part.
Brief Summary: This is a pragmatic randomized controlled study. The purpose of the study is to evaluate the practice and effect of customised physiotherapy on preterm infants'motor development when the intervention is performed over a period of three weeks while the infant resides in the neonatal intensive care unit. The study will also attempt to analyze the parents' experiences in being actively involved in education and practice of the intervention designed to promote the child's motor development, and the effects on the parent-child relationship in the short and long term.The children are followed up until a corrected age of two years. This study consists of a pragmatic randomized controlled trial and a qualitative study.


Options:
A: Arm Label: Term group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care program group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Clinic-based interveniton program group; Type: EXPERIMENTAL; Interventions: Behavioral: clinic-based intervention program and home-based intervention program | Arm Label: Home-based interveniton program group; Type: EXPERIMENTAL; Interventions: Behavioral: clinic-based intervention program and home-based intervention program | Intervention Type: BEHAVIORAL; Name: clinic-based intervention program and home-based intervention program; Assigned to Arm(s): Clinic-based interveniton program group, Home-based interveniton program group
B: Arm Label: Individually customized physiotherapy; Type: OTHER; Interventions: Other: Individually customized physiotherapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Individually customized physiotherapy; Assigned to Arm(s): Individually customized physiotherapy
C: Arm Label: Implement Family Integrated Care; Type: EXPERIMENTAL; Interventions: Other: Implement Family Integrated Care | Arm Label: Monitor Standard Practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implement Family Integrated Care; Assigned to Arm(s): Implement Family Integrated Care
D: Arm Label: Primebrain; Type: EXPERIMENTAL; Interventions: Other: Primebrain | Arm Label: usual care; Type: OTHER; Interventions: Other: Primebrain | Intervention Type: OTHER; Name: Primebrain; Assigned to Arm(s): Primebrain, usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Parental Participation in Individually Customized Physiotherapy for Preterm Infants in the Neonatal Intensive Care Unit: Effects and Experiences. The Pragmatic Randomized Controlled Part.
Brief Summary: This is a pragmatic randomized controlled study. The purpose of the study is to evaluate the practice and effect of customised physiotherapy on preterm infants'motor development when the intervention is performed over a period of three weeks while the infant resides in the neonatal intensive care unit. The study will also attempt to analyze the parents' experiences in being actively involved in education and practice of the intervention designed to promote the child's motor development, and the effects on the parent-child relationship in the short and long term.The children are followed up until a corrected age of two years. This study consists of a pragmatic randomized controlled trial and a qualitative study.


Options:
A: Arm Label: CareToy; Type: EXPERIMENTAL; Interventions: Device: CareToy | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Intervention Type: DEVICE; Name: CareToy; Assigned to Arm(s): CareToy | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Intervention Type: BEHAVIORAL; Name: Sensitizing parents; Assigned to Arm(s): N/A
C: Arm Label: Individually customized physiotherapy; Type: OTHER; Interventions: Other: Individually customized physiotherapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Individually customized physiotherapy; Assigned to Arm(s): Individually customized physiotherapy
D: Arm Label: Term group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care program group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Clinic-based interveniton program group; Type: EXPERIMENTAL; Interventions: Behavioral: clinic-based intervention program and home-based intervention program | Arm Label: Home-based interveniton program group; Type: EXPERIMENTAL; Interventions: Behavioral: clinic-based intervention program and home-based intervention program | Intervention Type: BEHAVIORAL; Name: clinic-based intervention program and home-based intervention program; Assigned to Arm(s): Clinic-based interveniton program group, Home-based interveniton program group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Duloxetine or Pregabalin in Monotherapy Versus Combination Therapy of Both Drugs in Patients With Painful Diabetic Neuropathy "The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study"
Brief Summary: This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not responded to the standard recommended dose of either drug. It will provide an answer to a common clinical question, namely, is it better to increase the dose of the current monotherapy or to combine both treatments early on, in patients who do not respond to standard doses of duloxetine or pregabalin.


Options:
A: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Duloxetine placebo; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone placebo; Assigned to Arm(s): 1, 2, 3, 4
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin+Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin, Drug: Placebo | Arm Label: Duloxetine + Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
Brief Summary: In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease:

* To confirm the superiority of TRK-100STP over placebo
* To determine the recommended therapeutic dose in the 2 doses of TRK-100STP
* To assess the safety of TRK-100STP


Options:
A: Arm Label: Clopidogrel group; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor group; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel group | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor group
B: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Acetylasalicylic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Acetylasalicylic acid
C: Arm Label: Standard Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Arm Label: Intensive Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Stop smoking; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Glucose lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Blood pressure lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Lipid lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm
D: Arm Label: TRK-100STP; Type: EXPERIMENTAL; Interventions: Drug: TRK-100STP high dose, Drug: TRK-100STP low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TRK-100STP high dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: TRK-100STP low dose; Assigned to Arm(s): TRK-100STP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD
Brief Summary: The purpose of this study is to examine the effects of glucocorticoid administration following traumatic memory reactivation on psychiatric symptoms in veterans with combat-related PTSD, in addition to examining the effects of glucocorticoid administration following traumatic memory reactivation on physiological responses to veteran's personal combat memories. The following hypotheses will be tested:

1. Subjects who receive an exogenous glucocorticoid after traumatic memory reactivation will demonstrate fewer PTSD and depression symptoms one week later, compared to those who receive a placebo after traumatic memory reactivation.
2. The glucocorticoid reduction effects will be cumulative; that is, reduction will persist, and further post-reactivation glucocorticoid administration will further reduce symptoms
3. Decreases in PTSD and depression symptoms will persist at 1, 3, and 6 months for subjects receiving an exogenous glucocorticoid compared to those subjects receiving placebo
4. Subjects who receive an exogenous glucocorticoid after traumatic memory reactivation will demonstrate decreased physiological responses one week later, compared to those who receive a placebo after traumatic memory reactivation.
5. As with the psychological measures, suppression of the physiological measures will demonstrate both persistence over time and accumulation with subsequent post-reactivation glucocorticoid administration.


Options:
A: Arm Label: Arm 1: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Arm 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (sugar pill) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm 1: Dexamethasone | Intervention Type: DRUG; Name: Placebo (sugar pill); Assigned to Arm(s): Arm 2: Placebo
B: Arm Label: N-Acetylcysteine; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): N-Acetylcysteine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm 1; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm 1
D: Arm Label: Experimental ketamine group; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Active control midazolam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Experimental ketamine group | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Active control midazolam group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Evaluation of Closed Loop Ventilation and Oxygen Controller
Brief Summary: The study compares automated settings (Intellivent) with protocolized settings of the ventilator after cardiac surgery. The settings concern the respiratory rate, the inspiratory and expiratory pressure and FiO2. The aim of the study is to demonstrate that automated settings are feasible and safe.

The study design is a randomized controled study. 30 patients will be ventilated with automated mode and 30 patients with protocolized settings after cardiac surgery.

The hypothesis is that the automated mode allows a safer ventilation with better maintain of the patient in predefined optimal zone of ventilation.


Options:
A: Intervention Type: DEVICE; Name: SmartCare/PS; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Smartcare/PS | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Smartcare/PS; Assigned to Arm(s): 1
C: Arm Label: Automated settings; Type: EXPERIMENTAL; Interventions: Device: Hamilton ventilator (G5 modify to S1) Automated settings | Arm Label: protocolized settings; Type: ACTIVE_COMPARATOR; Interventions: Other: Hamilton ventilator (G5) protocolized settings | Intervention Type: DEVICE; Name: Hamilton ventilator (G5 modify to S1) Automated settings; Assigned to Arm(s): Automated settings | Intervention Type: OTHER; Name: Hamilton ventilator (G5) protocolized settings; Assigned to Arm(s): protocolized settings
D: Arm Label: Adaptive support ventilation in ARDS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: type of mechanical ventilation | Arm Label: conventional ventilation strategy in ARDS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: type of mechanical ventilation | Intervention Type: PROCEDURE; Name: type of mechanical ventilation; Assigned to Arm(s): Adaptive support ventilation in ARDS, conventional ventilation strategy in ARDS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Brief Summary: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
B: Arm Label: Sertraline/omega-3 supplement; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline/omega-3 | Arm Label: Sertraline/corn oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline/Corn Oil | Intervention Type: DRUG; Name: Sertraline/omega-3; Assigned to Arm(s): Sertraline/omega-3 supplement | Intervention Type: DRUG; Name: Sertraline/Corn Oil; Assigned to Arm(s): Sertraline/corn oil
C: Arm Label: Web-based behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: web-based multifactorial intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: Behavioral: web-based multifactorial intervention | Intervention Type: BEHAVIORAL; Name: web-based multifactorial intervention; Assigned to Arm(s): Usual care, Web-based behavioral intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy, Other: Usual cardiological care | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information session, Other: Usual cardiological care | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Information session; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Usual cardiological care; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Brief Summary: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).


Options:
A: Arm Label: Nurse Practitioner Led-Care; Type: EXPERIMENTAL; Interventions: Other: Nurse Practitioner Led-Care | Arm Label: Cardiologist Led-Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Cardiologist Led-Care | Intervention Type: OTHER; Name: Nurse Practitioner Led-Care; Assigned to Arm(s): Nurse Practitioner Led-Care | Intervention Type: OTHER; Name: Cardiologist Led-Care; Assigned to Arm(s): Cardiologist Led-Care
B: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
C: Arm Label: Subject on Motivational Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Arm Label: Subject Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Subject on Motivational Interview | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Subject Control
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
Brief Summary: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients. The registry was used to document global baseline characteristics, current treatment strategies and outcome measures. Characterisation of a number of AF sub-populations was also completed. GARFIELD-AF is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).


Options:
A: Arm Label: CLOSE guided PVI and insertable cardiac monitor; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation; Assigned to Arm(s): CLOSE guided PVI and insertable cardiac monitor
B: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention group | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group
C: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A
D: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE

Answer: C